Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 8 5 W ELECTROLYTES versus NEPHRAMINE 5 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 8 5 W ELECTROLYTES versus NEPHRAMINE 5 4.
AMINOSYN II 8.5% W/ELECTROLYTES vs NEPHRAMINE 5.4%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and provide nitrogen for metabolic processes. Electrolytes maintain acid-base balance and osmotic pressure.
Provides essential amino acids for protein synthesis in patients with renal impairment, reducing nitrogen waste accumulation.
1 to 1.5 g amino acids/kg/day intravenously, typically infused over 12-24 hours.
500 mL to 1000 mL intravenously over 8-24 hours, containing 5.4% amino acids, typically as a component of total parenteral nutrition; dose adjusted based on metabolic needs and protein requirements (usual 0.8-1.5 g/kg/day amino acids).
None Documented
None Documented
Variable; amino acids typically have half-lives of minutes to hours; free amino acids in plasma have t1/2 of 10-30 minutes for most
1-2 hours (endogenous amino acid pool turnover); clinical context: continuous infusion required to maintain plasma levels.
Renal >90% (as amino acids and metabolites); fecal <5%
Renal: >90% as amino acids and metabolites. Biliary/fecal: negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution